1859-37-6

Basic information

• Product Name: CHEMBRDG-BB 4009817
• Synonyms: TIMTEC-BB SBB005696;CHEMBRDG-BB 4009817;1-(1-METHYL-4-PHENYLPIPERIDIN-4-YL)METHANAMINE;1-(1-methyl-4-phenylpiperidin-4-yl)methanamine(SALTDATA: FREE);(1-methyl-4-phenyl-4-piperidinyl)methanamine;(1-methyl-4-phenyl-4-piperidyl)methanamine;(1-methyl-4-phenyl-4-piperidyl)methylamine;(1-methyl-4-phenyl-piperidin-4-yl)methanamine
• CAS NO: 1859-37-6
• Molecular Formula: C₁₃H₂₀N₂
• Molecular Weight: 204.31
• Mol File: 1859-37-6.mol

Chemical Properties

• Boiling Point: 305.1°C at 760 mmHg
• Flash Point: 127.3°C
• Appearance: /
• Density: 0.997g/cm³
• Vapor Pressure: 0.000837mmHg at 25°C
• Refractive Index: 1.536
• PKA: 10.13±0.29(Predicted)
• CAS DataBase Reference: CHEMBRDG-BB 4009817(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 4009817(1859-37-6)
• EPA Substance Registry System: CHEMBRDG-BB 4009817(1859-37-6)

Safety Data

• Hazardous Substances Data: 1859-37-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H20N2/c1-15-9-7-13(11-14,8-10-15)12-5-3-2-4-6-12/h2-6H,7-11,14H2,1H3

Upstream product

• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 71258-18-9 1-benzyl-4-phenyl-piperidine-4-carbonitrile; hydrochloride 
• 3627-62-1 1-methyl-4-phenyl-piperidine-4-carbonitrile 
• 60-29-7 diethyl ether 

Downstream Products

• 1062653-98-8 C₂₈H₃₆N₆O 
• 96004-85-2 bis-(1-methyl-4-phenyl-[4]piperidylmethyl)-amine 
• 46475-80-3 methyl-(1-methyl-4-phenyl-piperidin-4-ylmethyl)-amine 
• 103097-20-7 N-(1-methyl-4-phenyl-[4]piperidylmethyl)-glycine-dimethylamide 
• 103641-15-2 N-(1-methyl-4-phenyl-[4]piperidylmethyl)-glycine-diethylamide 
• 110437-05-3 N,N-diethyl-β-alanine-[(1-methyl-4-phenyl-[4]piperidylmethyl)-amide] 
• 102709-04-6 N,N-diethyl-glycine-[(1-methyl-4-phenyl-[4]piperidylmethyl)-amide] 
• 7475-58-3 N-(1-methyl-4-phenyl-[4]piperidylmethyl)-formamide 
• 102552-23-8 benzylidene-(1-methyl-4-phenyl-[4]piperidylmethyl)-amine 
• 112224-04-1 (1-methyl-4-phenyl-[4]piperidylmethyl)-phenethyliden-amine 
• 103153-40-8 N-(1-methyl-4-phenyl-[4]piperidylmethyl)-β-alanine-dimethylamide 

Relevant articles and documents

Muscarinic acetylcholine receptor binding affinities of pethidine analogs

A series of pethidine analogs were synthesized and their affinities for the [3H]N-methyl-scopolamine (NMS) binding site on muscarinic acetylcholine receptors (mAChRs) were determined using M1, M3 or M5 human mAChRs expressed by Chinese hamster ovary (CHO) cell membranes. Compound 6b showed the highest binding affinities at M1, M3 and M5 mAChRs (Ki = 0.67, 0.37, and 0.38 μM, respectively).

Duraglutin artificial antigen and preparation method thereof

The invention provides a duramine artificial antigen and a preparation method thereof. The nitrile group of the 4-phenylpiperidine-4-carbonitrile is ingeniously reduced into the amino group; carboxylgroups capable of being used for crosslinking are introduced, so the characteristic original appearance of a duraglutin main ring is maintained; butanedioic anhydride is introduced, so acetyl functional groups on a duraglutin side chain is maintained on the said chain; the hapten synthesized by the process can maintain the characteristic group original appearance of duraglutin, and the synthesizedcorresponding artificial antigen has good specificity. The preparation process is simple, and the raw material source is not limited; the prepared artificial antigen can be used for animal immunization to obtain a corresponding duraglutin antibody, has strong antibody specificity, can be used in immunoassay, is suitable for research of various duraglutin immunoassay methods, and can be used as akey raw material for production of a duraglutin immunochromatographic kit.

THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS

The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease

NAPHTHAMIDE DERIVATIVES AND THEIR USE

Compounds having the following structure wherein R1, R2, R3, R4, m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.